82

DAFTAR PUSTAKA

1. Ozougwu, J. C.1, Obimba, K. C.2, Belonwu, C. D.3, and Unakalamba, C. B.

The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus.

Journal of Physiology and Pathofisiology. 2013 Sep 4 (4): 46-57.

2. American Diabetes Association. Diagnosis and classification of diabetes

mellitus. Diab Care; 2013: S67-74.

3. Hyun Soon Lee. Mechanisms and Consequences of TGF-ß Overexpression by

Podocytes in Progressive Podocyte Disease. 2012; 347(1): 129–140.

4. Francisco J. López-Hernández & Jose M. López-Novoa. Role of TGF-β in

chronic kidney disease: an integration of tubular, glomerular and vascular

effects. Cell Tissue Res (2012) 347:141–154

5. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-Beta as

the major mediator. J Am Soc Nephrol 2004;15: S55-7

6. Lee HS, Song CY. Differential role of mesangial cells and podocytes in TGF-

beta-induced mesangial matrix synthesis in chronic glomerular disease. 2009

Jul;24(7):901-8.

7. A. Iswara. Efek Pemberian Morinda citrfolia Pada Ginjal Diabetes Nefropaty

Tikus Spraque Dawley Diabetes Diinduksi STZ; Dengan Kajian Kadar

Albumin Urin, TGF-ß serum dan Ekspresi Kolagen. 2011. Tesis Biomedik

Undip.

8. Lee Wei Har, Intan safinar Ismail. Antioksidant Activity Total Phenolics and

Total flavonoids of Syzygium polyanthum (Wight) Walp Leaves. June 2012;

2(2): 219-288.

9. Djoko Wahyono, Susanti Aktivitas Hipoglikemik Ekstrak Etanolik Daun

Salam (Syzygium polyanthum (Wight) Walp) Dan Pengaruhnya Terhadap

Stimulasi Parasimpatik Pada Kelinci Jantan Yang Dibebani Glukosa.

10. Widharna RM, Ferawati, Herdiati L, Surjadhana A, Jonosewojo A,

Widjajakusuma EC. Antidiabetic Properties of Andrographis peniculata Nees

and Eugenia polyantha Wight Leaves in Wistar Rats by Oral Glucose

Tolerance Test. Jurnal Tumbuhan Obat Indonesia. Des 2010; 3 (2).

11. Lelono, RAA; Tachibana, Sanro. Preliminary Studies of Indonesian Eugenia

polyantha Leaf Extracts as Inhibitors of Key Enzymes for Type 2 Diabetes.

Journal of Medical Sciences 13.2 (2013): 103-110

83

12. Perumal S, Mahmud R, Piaru SP, et al. Potenstial antiradical activity and

cytotoxicity assessment of Ziziphus mauritiana and Syzygium polyanthum. Int

J of Pharm. 2012;8(6): 534-41.

13. Szkudelski T, The Mechanism of Alloxan and Streptozotocin Action in ß-Cell

of the Rat Pancreas, Physiological Research, 2001; (50) 536-546

14. Partini Pudjiastuti Trihono. Peran Transforming Growth Factor-ß1 Terhadap

Penyakit Ginjal. Sari Pediatri, Juni 2011; (13): 1

15. Tisna Tyasasmaya, Dhirgo Adji. Peranan Transforming Growth Factor β-1

(TGF β-1) dalam Perkembangan Penyakit Jantung Akibat Induksi Diet

Lemak Tinggi. Jurnal Sains Veteriner. Juli 2012; 30 (1): 0126 – 0421.

16. Hyun Soon Lee. Pathogenic Role of TGF-β in Diabetic Nephropathy.

Diabetes & Metabolism. Lee. 2013; S9

17. Paine. SK, Basu A, Mondal LK, Sen A, Choudhuri S, Chowdhury IH, Saha

A, Bhadhuri G, Mukherjee A, Bhattacharya B. Association of vascular

endothelial growth factor, transforming growth factor beta, and interferon

gamma gene polymorphisms with proliferative diabetic retinopathy in

patients with type 2 diabetes. 2012; (18): 2749-2757.

18. M. Bîcu, M. Moţa, M. Panduru, C. Grăunţeanu, E. Moţa. Oxidative stress in

diabetic kidney disease.rom. 2010; 48 (4) 307–312

19. P.Zhang, Y.Cai, A.Soofi, and G.R. Dressler. Activation Of Wnt11 by

Transforming Growth Factor-ß Drives Mesenchymal Gene Expression

Through Non-Cononical wnt Protein Signaling In Renal Ephitelial Cells.

2012; 287(25): 21290–21302.

20. Yogesh M. S, Umesh S. D, Harini B. Mesangial Pathology in Glomerular

Disease. Targets for teraupetic intervention. 2010; 1337-1343.

21. A.Ghayur and Peter J. Margetts. Transforming growth factor-beta and the

glomerular filtration barrier Kidney Res Clin Pract. 2013 March 1; 32(1): 3-

10.

84

22. K.B Gomes, K.F Rodrigues, and A.P Fernandes. The Role of Transforming

Growth Factor-Beta in Diabetic Nephropathy. Journal of Medical Genetics

Volume 2014 (2014), Article ID 180270.

23. H.Ibrahim, A.Hanim Bt Ismail, SB.Ismail, WM.Wan Bebakar. The use of

HbA1C in the diagnosis of diabetes mellitus type 2 in high risk subjects. Int J

Diabetes & Metab (2010) 18:25-28

24. WHO. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes

Mellitus. Abbreviated Report of a WHO Consultation. 2011.

25. CM. Sultanpur, Deepa K & SV. Kumar. comprehensive review on HbA1c in

diagnosis of diabetes mellitus. July 2010; 3 (2): 0976 – 044

26. J.Prins, BB Van der meijden, EAW.Blokland, JPM.Wielders and

RJ.Kraaijenhagen. Hemoglobin disorders detected in diabetic patients by

HbA1c analysis. Ned Tijdschr Klin Chem Labgeneesk 2005; (30): 4

27. RD.Mahajan, B.Mishra. Using Glycated Hemoglobin HbA1c for diagnosis of

Diabetes mellitus: An Indian perspective. Int J Biol Med Res. 2011; 2(2):

508-512

28. Brownlee M. Banting Lecture 2004. The Pathobiology Of Diabetic

Complications. A Unfiying Mechanism Diabetes. 2005;54;1615-35.

29. C.Campos, MD, MPH,CDE. Chronic Hyperglycemia and Glucose Toxicity:

Pathology and Clinical Sequelae. November 2012; 124(6): 0032-5481, e-

1941-9260

30. V. Sharma and Sharma PL. Diabetes and Metabolism. Role of Different

Molecular Pathways in the Development of Diabetes-Induced Nephropathy. J

Diabetes Metab 2013, (9)

31. Vilsu P. Patel, V. Lambole, B. N. Shah, P. Shah and Dhiren P. Shah.A Review

On Oxidative Stress And Diabetic Complications. 1 Apr-Jul 2013; 4 (3):

0976-7908

32. S. de M. Bandeira, L.José S. da Fonseca, Glaucevane da S. G. Luíza A.

Rabelo, Marília O. F. Goulart, and SML. Vasconcelos. Oxidative Stress as an

85

Underlying Contributor in the Development of Chronic Complications in

Diabetes Mellitus.

33. H. Kobori, M. Nangaku, G. Navar, and A. Nishiyama. The Intrarenal Renin-

Angiotensin System: From Physiology to the Pathobiology of Hypertension

and Kidney Disease. Pharmacol Rev. 2007 September; 59(3): 251–287

34. Depkes RI. Materia Medika Indonesia. Jakarta : Depkes RI, 1980.

35. Murhadi, Suharyono AS, Susilawati. Aktivitas antibakteri ekstrak daun salam

(Syzygium polyantha) dan daun pandan (pandanus amaryllifollus). 2007;

18:(1)

36. A.Sumono, A.Wulan SD. The Use of Bay Leaf (Eugenia polyantha Wight) in

Densitry. Majalah Kedokteran Gigi. July-September 2008; 41(3)

37. Mun’im A, Hanani E. Fisioterapi Dasar. Jakarta: Dian Rakyat.

38. Yohana ANA. Khasiat Tanaman Obat. Jakarta : Pustaka Buku Murah, 2008.

39. Herra Studiwan dan Mulja Hadi Santosa. Uji Aktivitas Penurun Kadar

Glukosa Darah Ekstrak Daun Eugenia polyantha pada Mencit yang Diinduksi

Aloksan. Media Kedokteran Hewan. Mei 2005; 21(2) .

40. Melhelm MF, Craven PA, Liachenko J and Derubertis FR. α-Lipoic Acid

Attenuates Hyperglycemia and Prevents Glomerular Mesangial Matrix

Expansion in Diabetes. 2002; 13: 108-16.

41. Makhyan Jibril Al-Farabi. Antibodi terhadap Advanced Glycation End

Product, Cara Mutakhir Pencegahan Komplikasi Diabetes Melitus. CDK-210.

2013; 40(11).

42. Kusuma IW, Kuspradi H, Arung ET, et al. Biological activity and

phytochemical analysis of three Indonesian medical plants, Murraya koenigii,

Syzygium polyanthum and Zingiber purpurae. Elsevier. 2011 Jan;4(1) :

75−79.

43. Rini Handayani, Joko Sulistyo. 2008. Sintesis senyawa flavonoid-α-glikosida

secara reaksi transglikosilasi enzimatik dan aktivitasnya sebagai antioksidan.

B i o d i v e r s i t a s. januari 2008; 9 (1412-033) 1: 1-4.

44. A.Redha. Flavonoid : struktur, Sifat Antioksidan dan peranannya dalam

sistem biologis. Sep. 2010; 9 (2): 196-202

86

45. Ratna Handayani, L. B. S Kardono, Jovita Merilla Wulansari. Aktivitas

antihiperglikemia pada functional drink daun salam (eugenia polyantha)

sebagai inhibitor enzim α-glukosidase. Oktober 2006; 4 (2): 1-4

46. Wahyu W, Ratu S, Rymond R, Marlinda S. Penapisan Aktivitas Superoksida

Dismutase pada Berbagai Tanaman. Juli 2005; 5(1): 2-15.

47. Vienna Saraswaty. Alpha Glucosidase Inhibitory Activity From Syzigium sp.

Teknologi Indonesia 2010; 33(1): 33–37.

48. Alejandro D. Bolzán, Martha S. Bianchi. Genotoxicity of Streptozotocin.

Mutation Research .2002. (512) 121–134

49. N.Sakata, G.Yoshimatsu, H.Tsuchiya, S.Egawa, and M.Unno. Review Article

Animal Models of Diabetes Mellitus for Islet Transplantation. 12 December

2012;

50. J.G. Mabley, Wilma L.S.Pinzon, G.R. Hasko , Andrew L. Salzman, A.

Rabinovitch, E.Kun & C.SzaboÂ. Inhibition of poly (ADP-ribose) synthetase

by gene disruption or inhibition with 5-iodo-6-amino-1,2-benzopyrone

protects mice from multiple-low-dose streptozotocin-induced diabetes. 2001

133: 909 – 919

51. Melanie L Graham, Jody L Janecek, Jessica A Kittredge, Bernhard J Hering,

and Henk-Jan Schuurman. The Streptozotocin-Induced Diabetic Nude Mouse

Model: Differences between Animals from Different Sources. August 2011;

61(4): 356–360

52. Akbarzadeh A, Norouzian D, Mehrabi MR, Jamshidi S, Farhangi A, Allah A,

Mofidian S, Lame Rad B. Induction of diabetes by streptozotocin in rats.

2007; 22: 60-64

53. Sastroasmoro S dan Ismail. Dasar-dasar metodologi penelitian klinis. Edisi 3.

Jakarta : Sagung Seto, 2008 : 93-111.

54. Cha DR, Kang YS, Sang Youb Han YHJea. Vascular Endothelial Growth

Factor is Increased During Early Stage of Diabetic Nephrophaty in Tipe II

Diabetic Rats. 2004; 81-84

55. Arora S, Ojha SK, Vohora D. Characterisation of Streptozotocin Induced

Diabetes Melitus in Swiss Albino Mice. 2009; 3(2): 81-4.

87

56. Nakagawa, T., Kosugi, T., Haneda, M., Rivard, C. J. & Long, D. A.,

Abnormal Angiogenesis in Diabetic Nephropathy. Diabetes Journal 58,

1471-1478 (2009).